Higher expression levels of YTHDF1, ATG2A, and ATG14 were associated with worse outcomes in patients with HCC, indicating that YTHDF1 and its target genes ATG2A and ATG14 may serve as promising biomarkers in predicting prognosis and in developing treatment strategies for HCC. This evidence concerns the gene ATG2A and hepatocellular carcinoma.